Iron-binding characteristics of neuromelanin of the human substantia nigra

Biochemical Pharmacology - Tập 66 - Trang 489-494 - 2003
Kay L. Double1,2, Manfred Gerlach3, Volker Schünemann4, Alfred X. Trautwein4, Luigi Zecca5, Mario Gallorini6, Moussa B.H. Youdim7, Peter Riederer2, Dorit Ben-Shachar8
1Prince of Wales Medical Research Institute, University of New South Wales, Barker Street Randwick, Sydney NSW 2031, Australia
2Clinical Neurochemistry, National Parkinson Foundation Center of Excellence Research Laboratory, Department of Psychiatry, University of Würzburg, Würzburg, Germany
3Clinical Neurochemistry, Department of Child and Youth Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany
4Institute of Physics, Medical University of Lübeck, Lübeck, Germany
5Institute of Biomedical Technologies—CNR, Segrate, Milano, Italy
6Center of Radiochemistry and Activation Analysis—CNR, University of Pavia, Pavia, Italy
7Department of Pharmacology, B. Rappaport Faculty of Medicine, Eve Topf Neurodegenerative and National Parkinson Foundation Centers, Technion, Haifa, Israel
8Laboratory of Psychobiology, Department of Psychiatry, B. Rappaport Faculty of Medicine, Rambam Medical Centre and Technion, Haifa, Israel

Tài liệu tham khảo

Aime, 1997, EPR investigations of the iron domain in neuromelanin, Biochem. Biophys. Acta, 1361, 49 Aime, 2000, Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson’s disease, Mov. Disord., 15, 977, 10.1002/1531-8257(200009)15:5<977::AID-MDS1032>3.0.CO;2-Q Aime S, Fasano M, Bergamasco B, Lopiano L, Quattrocolo G. Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin. In: Battistini L, Scarlato G, Caraceni T, Ruggieri S, editors. Advances in neurology. Philadelphia: Lippencott-Raven Publishers; 1996. p. 263–70. Bartzokis, 2000, MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntington’s disease, Cell Mol. Biol. (Noisy-le-Grand), 46, 821 Ben-Shachar, 1991, Iron–melanin interaction and lipid peroxidation: implications for Parkinson’s disease, J. Neurochem., 57, 1609, 10.1111/j.1471-4159.1991.tb06358.x Berg, 2001, Brain iron pathways and their relevance to Parkinson’s disease, J. Neurochem., 79, 225, 10.1046/j.1471-4159.2001.00608.x Bolzoni, 2002, Magnetic investigations of human mesencephalic neuromelanin, Biochem. Biophys. Acta, 1586, 210, 10.1016/S0925-4439(01)00099-0 Bridelli, 1999, The structure of neuromelanin and its iron binding site studied by infrared spectroscopy, FEBS Lett., 457, 18, 10.1016/S0014-5793(99)01001-7 Castellani, 2000, Sequestration of iron by Lewy bodies in Parkinson’s disease, Acta Neuropathol., 100, 111, 10.1007/s004010050001 Chasteen, 1999, Mineralization in ferritin: an efficient means of iron storage, J. Struct. Biol., 126, 182, 10.1006/jsbi.1999.4118 Dexter, 1989, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease, J. Neurochem., 52, 1830, 10.1111/j.1471-4159.1989.tb07264.x Double, 2002, Influence of neuromelanin on oxidative pathways within the human substantia nigra, Neurotox. Teratol., 24, 621, 10.1016/S0892-0362(02)00218-0 Double, 1999, The significance of neuromelanin in Parkinson’s disease, Drug News Develop., 12, 333 Double, 2000, Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins, J. Neurochem., 75, 2583, 10.1046/j.1471-4159.2000.0752583.x Double KL, Gerlach M, Youdim MBH, Riederer P. Impaired iron homeostatsis in Parkinson’s disease. In: Riederer P, Calne DB, editors. Advances in research on neurodegeneration. Vienna: Springer; 2000. p. 37–58. Enochs, 1993, Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy, J. Neurochem., 61, 68, 10.1111/j.1471-4159.1993.tb03538.x Gerlach, 2000, Strategies for the protection of dopaminergic neurons against neurotoxicity, Neurotox. Res., 2, 99, 10.1007/BF03033788 Gerlach, 1995, Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra, J. Neurochem., 65, 923, 10.1046/j.1471-4159.1995.65020923.x Gibb, 1992, Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrastriatal projections and differential neuron susceptibility in Parkinson’s disease, Brain Res., 581, 283, 10.1016/0006-8993(92)90719-P Good, 1992, Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson’s disease: a LAMMA study, Brain Res., 593, 343, 10.1016/0006-8993(92)91334-B Harrison, 1996, The ferritins: molecular properties, iron storage function and cellular regulation, Biochem. Biophys. Acta, 1275, 161 Hirsch, 1988, Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson’s disease, Nature, 28, 345, 10.1038/334345a0 Jellinger, 1992, Iron–melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis, J. Neurochem., 59, 1168, 10.1111/j.1471-4159.1992.tb08362.x Kastner, 1992, Is the vulnerability of neurons in the substantia nigra of patients with Parkinson’s disease related to their neuromelanin content?, J. Neurochem., 59, 1080, 10.1111/j.1471-4159.1992.tb08350.x Krol, 1998, Photoprotective actions of natural and synthetic melanins, Chem. Res. Toxicol., 11, 1434, 10.1021/tx980114c Kropf, 1998, XAFS studies of iron sites in synthetic and natural neuromelanin, Biophys. J., 75, 75 Lopiano, 2000, Q-band EPR investigations of neuromelanin in control and Parkinson’s disease patients, Biochem. Biophys. Acta, 1500, 306 Mochizuki, 1993, Iron–melanin complex is toxic to dopaminergic neurons in nigrostriatal co-culture, Neurodegeneration, 2, 1 Nau-Staudt, 2001, Lipid peroxidation in porcine irises: dependence on pigmentation, Curr. Eye Res., 22, 229, 10.1076/ceyr.22.3.229.5511 Offen, 1997, Dopaminemelanin induces apoptosis in PC12 cells: possible implications for the etiology of Parkinson’s disease, Neurochem. Int., 31, 207, 10.1016/S0197-0186(96)00150-7 Pilas, 1988, The effect of melanin on iron associated decomposition of hydrogen peroxide, Free Radic. Biol. Med., 4, 285, 10.1016/0891-5849(88)90049-4 Riederer, 1989, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J. Neurochem., 52, 515, 10.1111/j.1471-4159.1989.tb09150.x Rozanowska, 1999, Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals, Free Radic. Biol. Med., 26, 518 Scalia, 1990, Lipid peroxidation in pigmented and unpigmented liver tissues: protective role of melanin, Pigment Cell Res., 3, 115, 10.1111/j.1600-0749.1990.tb00330.x Shima, 1997, Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study, Free Radic. Biol. Med., 23, 110, 10.1016/S0891-5849(96)00623-5 Sofic, 1988, Increased iron(III) and total iron content in post-mortem substantia nigra of parkinsonian brain, J. Neural Trans., 74, 199, 10.1007/BF01244786 Youdim, 1994, The enigma of neuromelanin in Parkinson’s disease substantia nigra, J. Neural Trans., 43, 113 Zareba, 1995, The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems, Biochem. Biophys. Acta, 1271, 343 Zecca, 2001, Iron, neuromelanin and ferritin content in substantia nigra of normal subjects at different ages. Consequences for iron storage and neurodegenerative processes, J. Neurochem., 76, 1766, 10.1046/j.1471-4159.2001.00186.x Zecca, 1992, The chemical characterization of melanin contained in substantia nigra of human brain, Biochim. Biophys. Acta, 1138, 6, 10.1016/0925-4439(92)90144-C Zecca, 1996, Interaction of neuromelanin and iron in substantia nigra and other areas of human brain, Neuroscience, 73, 407, 10.1016/0306-4522(96)00047-4 Zecca, 1993, Total and paramagnetic metals in human substantia nigra and its neuromelanin, J. Neural Trans. Park. Dis. Sect., 5, 203, 10.1007/BF02257675